While loss of the capillary microvasculature is a feature of the SNX model, as with CKD in humans, growth factors with primarily angiogenic effects, such as vascular endothelial growth factor (VEGF), do not attenuate proteinuria, hypertension or glomerulosclerosis despite preventing microvascular loss [41]. The gene discussed is VEGFA; the disease is glomerulosclerosis.